Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.86 Analyst target: $2.00 Upside: 132.86%
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and markets new therapies for the treatment of fibrosis and related diseases in the United States. The company is headquartered in South San Francisco, California.
See the full interactive analysis & chart →Informational only — not investment advice.